Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease - Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications

Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease - Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Polymer Journal - Volume 88, March 2017, Pages 524-552

Randall W. Moreadith, Tacey X. Viegas, Michael D. Bentley, J. Milton Harris, Zhihao Fang, Kunsang Yoon, Bekir Dizman, Rebecca Weimer, Brendan P. Rae, Xiuling Li, Christoph Rader, David Standaert, Warren Olanow,